Notícias

These three Dividend Aristocrats under $100 offer steady payouts, reasonable payout ratios, and analyst-backed upside potential.

In Q1 2026, Abbott Laboratories reported a modest earnings beat, closed its US$21.00 billion Exact Sciences acquisition to expand in cancer diagnostics, and outlined a new volume-led Nutrition strategy after a 6% sales decline, while continuing to face significant infant formula litigation and regulatory scrutiny. These developments have prompted analysts and commentators to reassess Abbott’s execution risks and diversification benefits, balancing dilution from the Exact Sciences deal...

ABT shifts to a volume-led Nutrition strategy with pricing moves and new product launches after Q1 sales declined 6%.

Even as tech surges, many other sectors in the market are trading at surprisingly attractive prices.

Even as tech surges, many other sectors in the market are trading at surprisingly attractive prices.

(Bloomberg) -- President Donald Trump’s latest financial disclosures show that he made a slew of stock and bond purchases with major American companies in the first quarter of the year totaling in the tens of millions of dollars and possibly more. Most Read from BloombergHormuz Oil Flows Creep Higher as More Supertankers ExitIran’s Kharg Island Oil Jetties Empty Again Yesterday, Satellite ShowsWhat Is The Thucydides Trap and Why Did Xi Raise It With Trump?Xi Tells US CEOs on Trump Visit That Chi

Abbott Laboratories (NYSE:ABT) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. Cramer highlighted it as one of the “greatest American companies,” as he said: …Let’s talk about some similarities that have now been popping up, okay? In 1999, we saw […]

Abbott Laboratories is under fresh scrutiny as price targets are reset, with some analysts trimming their expectations and others keeping fair value estimates such as US$118.64 broadly intact. The more cautious tone in recent research, including cuts to targets and removal from a key US conviction list, sits alongside ongoing supportive views that still see room for upside versus analysts’ own fair value work. As you read on, you will see how to track these shifting targets and use the...

Boston Scientific rides on cardiovascular device growth with FARAPULSE and WATCHMAN momentum, but margin pressure and weaker estimates cloud the outlook.

ABT's Q1 beat was overshadowed by Exact Sciences dilution, legal risks and weak Diagnostics trends as shares hit a 52-week low.

The latest generation of the coronary intravascular lithotripsy device is designed to be more flexible to help physicians navigate tight arteries to break up calcified deposits and restore blood flow.

Investing.com -- Abbott Laboratories is presenting a complex case for value seekers as its dividend yield climbs to a ten-year high, reflecting a stock price weighed down by the $21 billion Exact Sciences integration and nearly $500 million in upheld legal judgments.

How does a rising 3.4% dividend and a growing portfolio of drugs sound?

According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Abbott Laboratories (ABT) is back in focus after mixed first quarter results, a cut to its 2026 adjusted EPS outlook tied to the Exact Sciences acquisition, and a large baby formula legal verdict that raised fresh questions. See our latest analysis for Abbott Laboratories. The recent mix of weaker first quarter sentiment, the Exact Sciences related EPS guidance cut and the baby formula verdict has coincided with a sharp reset in expectations. The share price is down 15.9% over 30 days and...

This mortgage REIT generates income by originating and managing commercial real estate loans across the United States.

Blackstone Mortgage Trust originates senior commercial real estate loans globally, generating income primarily from interest and dividends.

The company combines strong device growth with an attractive valuation despite near-term headwinds.

Tandem Diabetes Care (NASDAQ:TNDM) reported record first-quarter pump shipments and sales for 2026, while reaffirming its full-year outlook as the diabetes technology company advances a shift toward pharmacy-channel reimbursement, expands direct international operations and prepares several product

ABT's Medical Devices segment posts 8.5% Q1 growth as Electrophysiology, Rhythm Management and Heart Failure deliver strong gains.

While Abbott Laboratories has underperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

If you are wondering whether Abbott Laboratories at around US$87.01 is starting to look like value, the recent share price performance gives you plenty to weigh up. The stock has seen a 4.2% decline over the last week, a 14.6% decline over the last month, and is down 29.9% year to date and 33.7% over the last year. Over the last few months, headlines around Abbott have focused on its position in medical devices and diagnostics, alongside broader sector sentiment that has affected many large...

By Daniella Parra Glucotrack, Inc. (Nasdaq: GCTK) said it has submitted an Investigational Device Exemption application to the FDA to begin a U.S. clinical study for its fully implantable continuous blood glucose monitoring technology. The company said it is designed to deliver real-time glucose readings without the need for an external wearable device. “Submission of […]

Abbott Laboratories (NYSE:ABT) released new late breaking clinical data on its advanced cardiac devices, focusing on pulsed field ablation and conduction system pacing. The data highlights patient outcomes for the TactiFlex Duo Ablation Catheter, UltiSynq CSP ICD lead, and AVEIR CSP leadless pacemaker in complex heart rhythm disorders. These results add fresh detail on Abbott's electrophysiology and device pipeline beyond its recently covered AI enabled imaging approvals. For anyone...

These stocks pay more than double the S&P 500 average and have modest valuations relative to the overall market.

Abbott’s business and dividend story remain intact even as the stock trades near 52‑week lows.

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

By Karen Roman Agilent Technologies, Inc. (NYSE: A) said it designated Michael Buckner as Chief Legal Officer, having previously served at Danaher as Vice President, Deputy General Counsel, and Chief M&A Counsel. Mr. Buckner has nearly 30 years of experience as a senior global legal executive with experience in complex transactions and regulatory environments, the […]

This company, which has raised its dividend for 54 consecutive years, is on sale.

Abbott Laboratories (NYSE:ABT) is one of the best medical device stocks to invest in right now. Abbott Laboratories (NYSE:ABT) announced on April 28 that it received the U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon™ 3.0 Software. Management stated that the milestone marks a considerable step forward for the […]